Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ramesh K. Ramanathan, MD
University of Pittsburgh
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Albert Einstein Comprehensive Cancer Center
The Bronx, New York, United States
- University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
- Lifespan: the Miriam Hospital
Providence, Rhode Island, United States
- Sarah Cannon-Minnie Pearl Cancer Center
Nashville, Tennessee, United States
- University of Texas - Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 1999
- Primary completion
- 31 Mar 2006
- Completion
- —
- Last update posted
- 8 Feb 2013
- Registered enrollment
- 32
- Registry id
- NCT00003995
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.